Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutations were preferentially detected in patients with adenocarcinomas, and the frequency of PIK3CA mutations in patients with squamous cell carcinomas was higher than that in patients with other histological cancer types.
|
31757465 |
2020 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Erratum: Adenosine induces intrinsic apoptosis via the PI3K/Akt/mTOR signaling pathway in human pharyngeal squamous carcinoma FaDu cells.
|
30867805 |
2019 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TROP2 increases growth and metastasis of human oral squamous cell carcinoma through activation of the PI3K/Akt signaling pathway.
|
31638186 |
2019 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
<i>PAR-2</i> promotes cell proliferation, migration, and invasion through activating PI3K/AKT signaling pathway in oral squamous cell carcinoma.
|
31213575 |
2019 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Transformed SCC acquired genomic alterations related to the PI3K/AKT/mTOR pathway, in addition to the initial EGFR mutation.
|
31319998 |
2019 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increased LGALS3BP promotes proliferation and migration of oral squamous cell carcinoma via PI3K/AKT pathway.
|
31302247 |
2019 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PI3K inhibitors such as PI-103, PI-828 and PX-866 may be developed as potential therapeutic agents for effective treatment of oral squamous cell carcinoma (OSCC) patients, associated with activated PI3K/Akt pathway.
|
30519710 |
2019 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The immunoregulatory protein B7-H3 promotes aerobic glycolysis in oral squamous carcinoma via PI3K/Akt/mTOR pathway.
|
31737114 |
2019 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Astaxanthin inhibits hallmarks of cancer by targeting the PI3K/NF-κΒ/STAT3 signalling axis in oral squamous cell carcinoma models.
|
31251469 |
2019 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This may be because pathways enriched in the TrkB high expressers, like those involving oncogenes NFE2L2, PIK3CA, and SOX2, are known to have SCC anatomic site-specific effects on progression.
|
31221127 |
2019 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data suggest that the PI3K/AKT pathway is related to cell survival and proliferation in oral squamous cell carcinoma through its interaction with Bcl-2 family members.<br />.
|
31759362 |
2019 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Licochalcone A inhibits cell proliferation, migration, and invasion through regulating the PI3K/AKT signaling pathway in oral squamous cell carcinoma.
|
31239711 |
2019 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Integrin-α5 promoted the progression of oral squamous cell carcinoma and modulated PI3K/AKT signaling pathway.
|
30909080 |
2019 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adenosine induces intrinsic apoptosis via the PI3K/Akt/mTOR signaling pathway in human pharyngeal squamous carcinoma FaDu cells.
|
29616118 |
2018 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
KRAS and EGFR mutations were significantly more frequent in adenocarcinomas: PIK3CA in squamous cell carcinomas.
|
29186353 |
2018 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The PI3K/AKT/mTOR pathway is frequently activated in various squamous cell carcinomas (SCCs).
|
30568499 |
2018 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PIK3CA gene copy number increase is associated with a favorable clinical outcome in HPV-negative OPCs treated with surgery ± postoperative radiotherapy.
|
29714670 |
2018 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
mTORis do not significantly change the immunohistochemical expression of molecules upstream of the mTOR inhibition (pmTOR, PI3K, pAkt), in cutaneous SCC.
|
29848679 |
2018 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Using samples from 122 patients, we established 41 NSCLC PDXs [30 adenocarcinoma (AD), 11 squamous cell carcinoma (SQ)], among which the following driver mutation were observed: 13 EGFR-mutant, 4 ALK-rearrangement, 1 ROS1-rearrangement, 1 PIK3CA-mutant, 1 FGFR1-amplification, and 2 KRAS-mutant.
|
30268457 |
2018 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Computational analysis indicated that miR-296-3p targeted PTEN, which regulates the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway and PTEN is involved in the carcinogenesis of SCC. miR-296-3p directly regulated PTEN expression in head and neck cancer cells, with PTEN protein levels decreased in 4/19 the SCCs (21.0%), as compared with those in the IPs (76.4%).
|
28693263 |
2017 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Whether they function as direct precursors to a less common form of squamous cell carcinoma will require further study, but carcinomas associated with these lesions might warrant testing for PIK3CA mutations to address this question.
|
27834349 |
2017 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Paraoxonase 3 promotes cell proliferation and metastasis by PI3K/Akt in oral squamous cell carcinoma.
|
27923688 |
2017 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The activated pathway in lung ADC and SCC mainly focuses on MAPK and PI3K with different key genes of each, respectively, and the activated pathway of SCLC mainly focuses on JAK-STAT pathway.
|
27845189 |
2017 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We have studied the prognostic importance of PIK3CA mutations as well as the relation to other markers in a large number of early stage lung cancers of squamous carcinoma subtype.
|
28024696 |
2017 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings offer a novel strategy that could potentially enhance the efficacy of PI3Kα inhibitors while mitigating dose-limiting toxicity in patients with head and neck squamous cell carcinomas.
|
28194032 |
2017 |